Abstract 【Objective】To investigate the correlation and clinical significance of the expression of miR-130a and recombinant human Runt-related transcription factor 3 (RUNX3) in esophageal squamous cell carcinoma. 【Methods】A total of 84 patients with esophageal squamous cell carcinoma who were treated in our hospital were collected. The cancer tissues and the corresponding adjacent tissues of patients at the time of surgery were taken for exam. The qRT-PCR was performed to detect the expression level of miR-130a in tissues; Western blot and immunohistochemical methods were performed to detect the expression of RUNX3 protein in tissues. All postoperative patients were followed up to investigate the effects of miR-130a and RUNX3 expression on the prognosis of patients with esophageal squamous cell carcinoma. 【Results】Compared with adjacent tissues,the expression level of miR-130a in esophageal squamous cell carcinoma tissues was higher (P<0.05),while the expression level of RUNX3 protein was lower (P<0.05). The expression levels of miR-130a and RUNX3 protein in esophageal squamous cell carcinoma were negatively correlated (P<0.05). The protein expression levels of miR-130a and RUNX3 were obviously correlated with T stage,cancer differentiation and lymph node metastasis (P<0.05). Kaplan-Meier survival curve analysis showed that the median survival time of patients with esophageal squamous cell carcinoma of high miR-130a expression was obviously shorter than that of patients with low miR-130a expression (P<0.05).Also the result showed that the median survival time of patients with esophageal squamous cell carcinoma with low RUNX3 expression was obviously shorter than that of patients with high RUNX3 expression (P<0.05). Multivariate Cox analysis showed that T staging (T3-T4),lymph node metastasis,high expression of miR-130a,and low expression of RUNX3 were independent risk factors for poor prognosis in patients with esophageal squamous cell carcinoma (P<0.05). 【Conclusion】The expression level of miR-130a is up-regulated and the expression level of RUNX3 protein is down-regulated in esophageal squamous cell carcinoma. The two are closely related to the poor prognosis of patients with esophageal squamous cell carcinoma. Patients with esophageal squamous cell carcinoma with high expression of miR-130a and low expression of RUNX3 may have a higher risk of poor prognosis.
YAO Hong-jun,HU Jing,YUAN Can-liang. Correlation and Clinical Significance of miR-130a and RUNX3 Expression in Esophageal Squamous Cell Carcinoma[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1165-1169.
[1] JANG R,DARLING G,WONG R K S. Multimodality approaches for the curative treatment of esophageal cancer[J].J Natl Compr Canc Netw,2015,13(2):229-238.
[2] LEE S H,JUNG Y D,CHOI Y S,et al. Targeting of RUNX3 by miR-130a and miR-495 cooperatively increases cell proliferation and tumor angiogenesis in gastric cancer cells[J].Oncotarget,2015,6(32):33269-33278.
[3] 律方,薛奇,邵康,等. 国际抗癌联盟-美国癌症联合委员会食管癌分期第7版临床应用的初步体会[J].中华肿瘤杂志,2012,34(6):461-464.
[4] HANAI Y,EMI M,IBUKI Y,et al. Distribution of lymph node metastasis in esophageal squamous cell carcinoma after trimodaltherapy[J].Ann Surg Oncol,2021,28(3):1798-1807.
[5] ZHANG H D,JIANG L H,SUN D W,et al. The role of miR-130a in cancer[J].Breast Cancer,2017,24(4):521-527.
[6] 许旭东,王银龙,朱友明,等. PJA1及miR-130a基因在口腔肿瘤组织中的表达及相关性分析[J].安徽医科大学学报,2017,52(11):44-48.
[7] YANG H O,ZHANG H Y,GE S H,et al. Exosome-Derived miR-130a activates angiogenesis in gastric vancer by targeting C-MYB in vascular endothelial cells[J].Mol Ther,2018,26(10):2466-2475.
[8] PARK J,KIM H J,KIM K R,et al. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma[J].Oncotarget,2017,8(6):9079-9092.
[9] 杨万广,裴辉,王万朋,等. Runx3及Twist在胃癌组织中的表达及临床意义[J].胃肠病学和肝病学杂志,2017,26(12):1337-1339.
[10] JIANG H,YU W W,WANG L L,et al. miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration,invasion and proliferation by targeting RUNX3[J].Oncol Rep,2015,34(3):1153-1161.
[11] 杨海平,张瑜,桑吉扎西. miR-130a在结直肠癌组织中的表达及其与预后的关系[J].中国肿瘤临床与康复,2018,25(6):641-644.
2022, Vol. 39 
